Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

$2.75
-0.19 (-6.46%)
-
Symbol PSTV
Price 2.75$
Beta 0.400
Volume Avrg. 1.04M
Market Cap 0.01B
Shares (2019) 1,384.01K
Last Div 0
Dividend Yield -
DCF Unlevered -876.86 Strong Sell
DCF Levered -724.36 Strong Sell
ROE -938.53% Strong Sell
ROA -46.87% Strong Sell
Operating Margin -52.26% Strong Sell
Debt / Equity 1902.50% Strong Buy
P/E -0.28 Neutral
P/B 2.64 Strong Buy

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) -162-183-210-242-275-301-338-357-379-402-414
Net Income -23-27-32-32-26-37-19-22-23-13-11
Stock Dividends 3-0---00----
Dividend Paid -------0----
Retained Earnings -183-210-242-275-301-338-357-379-402-414-425

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE 31222122132
Annual Depreciation -1112-121-03-11
Capital Expenditure -0-1-1-1-1-1-1-0-1-0-0
Net PPE 12221221323

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) 5544413131312110
New Purchases -----------
Intangible and Goodwill 5444131313121100

About


Dr. Marc Hedrick
Healthcare
Biotechnology
NasdaqGS

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. The company is headquartered in Austin, Texas and currently employs 37 full-time employees. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.